Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update

Posted: October 30, 2024 at 2:42 am

Phase 2a proof-of-concept study of SPR720 for the treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) did not meet its primary endpoint, based on planned interim analysis of 16 patients

Read the original here:
Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update

Related Posts